4/25/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – FLAGYL Comp. emätinpuikko

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Metronidazol

Metronidazol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.

  2. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser 1982;18:85-8.

  3. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22(4):825.

  4. Berget A, Weber T. [Metronidazole and pregnancy]. Ugeskr Laeger 1972;134:2085-9.

  5. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348-52.

  6. Burtin P, Taddio A, Ariburnu O et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.

  7. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-82.

  8. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998;105:322-7.

  9. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: A prospective controlled cohort study. Teratology 2001;63:186-92.

  1. Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.
  2. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser 1982;18:85-8.
  3. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22(4):825.
  4. Berget A, Weber T. [Metronidazole and pregnancy]. Ugeskr Laeger 1972;134:2085-9.
  5. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348-52.
  6. Burtin P, Taddio A, Ariburnu O et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.
  7. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-82.
  8. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998;105:322-7.
  9. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: A prospective controlled cohort study. Teratology 2001;63:186-92.
2 2
2 2

Nystatin

Nystatin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. P David Rogers; Damian J Krysan. Goodman & Gilman´s: The Pharmacological Basis of Therapeutics. 13. Access Medicine; 2018 [cited 2023-03-24].

  2. DrugBank Canada. DrugBank-nystatin. DrugBank [www]. DrugBank Canada. [cited 2023-03-24].

  3. Nystatin. Martindale 31st Ed. The Royal Pharmaceuticla Society. p. 413.

  4. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.

  5. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  6. Czeizel AE, Kazy Z, Puhó E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. Scand J Infect Dis 2003;35:830-5.

  7. TERIS. Nystatin. Available from www.micromedex.com. [cited 2023-03-24].

  8. Mavrogenis S, Urban R, Czeizel AE, Acs N. Maternal risk factors in the origin of isolated hypospadias: a population-based case-control study. Congenit Anom (Kyoto). 2014;54(2):110-5.

  1. P David Rogers; Damian J Krysan. Goodman & Gilman´s: The Pharmacological Basis of Therapeutics. 13. Access Medicine; 2018 [cited 2023-03-24].
  2. DrugBank Canada. DrugBank-nystatin. DrugBank [www]. DrugBank Canada. [cited 2023-03-24].
  3. Nystatin. Martindale 31st Ed. The Royal Pharmaceuticla Society. p. 413.
  4. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.
  5. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  6. Czeizel AE, Kazy Z, Puhó E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. Scand J Infect Dis 2003;35:830-5.
  7. TERIS. Nystatin. Available from www.micromedex.com. [cited 2023-03-24].
  8. Mavrogenis S, Urban R, Czeizel AE, Acs N. Maternal risk factors in the origin of isolated hypospadias: a population-based case-control study. Congenit Anom (Kyoto). 2014;54(2):110-5.